Crown Bioscience Inc.: Crown Bioscience Announces Merger with JSR Corporation

SAN DIEGO, 2017-12-21 17:59 CET (GLOBE NEWSWIRE) --
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International
(TWSE:ticker 6554) and a global drug discovery and development services company
providing translational platforms to advance oncology, inflammation,
cardiovascular and metabolic disease research, announced yesterday that they
will merge with and become a fully owned subsidiary of the JSR Corporation,
headquartered in Tokyo, Japan. The merger produces a fully integrated suite of
innovative solutions to support researchers through every stage of drug and
diagnostic development - from early research through manufacturing. 

The strategic merger integrates Crown Bioscience's leading translational
technology platform providing drug target validation, efficacy testing and
patient response characterization with JSR's in vitro diagnostic (IVD)
solutions, GMP manufacturing capabilities and worldwide distribution networks. 

"We are excited to join the JSR family of companies through this
innovation-driven strategic partnership," said Dr. Jean-Pierre Wery, Crown
Bioscience's Chief Executive Officer. "Crown Bioscience's core competencies in
preclinical and translational research combined with JSR's global footprint,
diagnostic solutions and manufacturing capabilities will provide a fully
integrated solution to help biopharmaceutical companies get drugs and
diagnostics to market more efficiently." 

The completion of the merger is expected to close before the end of the second
quarter of 2018. 

About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company
providing translational platforms to advance oncology, inflammation and
metabolic disease research. With an extensive portfolio of relevant models and
predictive tools, Crown Bioscience enables clients to deliver superior clinical
candidates. 

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[e-mail]